Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

BGB 30813

Next Previous
X
Search
Drug Profile

BGB 30813

Alternative Names: BGB-30813

Latest Information Update: 04 Jul 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator BeiGene
  • Class Antineoplastics
  • Mechanism of Action DGKZ protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase I Solid tumours

Most Recent Events

  • 04 Jul 2023 BGB 30813 is available for licensing as of 04 Jul 2023. https://www.beigene.com/partnering/
  • 01 Jul 2023 Phase-I clinical trials in Solid tumours in Australia (unspecified route) (NCT05904496)
  • 21 Jun 2023 Beigene plans a phase I trial in Solid tumours (Monotherapy, Combination therapy, Late stage disease, Inoperable/Unresectable, Metastatic disease) in USA, Australia, China and Spain (NCT05904496) (EudraCT2023-503996-38)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top